262 related articles for article (PubMed ID: 28529576)
41. MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1.
Jin S; He J; Li J; Guo R; Shu Y; Liu P
Thorac Cancer; 2018 Oct; 9(10):1262-1270. PubMed ID: 30126075
[TBL] [Abstract][Full Text] [Related]
42. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
43. FGFR1 Induces Acquired Resistance Against Gefitinib By Activating AKT/mTOR Pathway In NSCLC.
Zhang D; Han LL; Du F; Liu XM; Li J; Wang HH; Song MH; Li Z; Li GY
Onco Targets Ther; 2019; 12():9809-9816. PubMed ID: 31819480
[TBL] [Abstract][Full Text] [Related]
44. Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells
Chiu HY; Chiang CM; Yeh SP; Jong DS; Wu LS; Liu HC; Chiu CH
Oncol Lett; 2020 Nov; 20(5):206. PubMed ID: 32963612
[TBL] [Abstract][Full Text] [Related]
45. [Screening and identification of microRNAs related to acquired gefitinib-resistance in lung adenocarcinoma cell lines].
Qin X; Liu B; Li Y; You J; Zhou Q
Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):478-83. PubMed ID: 21645449
[TBL] [Abstract][Full Text] [Related]
46. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer.
Hidayat M; Mitsuishi Y; Takahashi F; Tajima K; Yae T; Miyahara K; Hayakawa D; Winardi W; Ihara H; Koinuma Y; Wirawan A; Nurwidya F; Kato M; Kobayashi I; Sasaki S; Takamochi K; Hayashi T; Suehara Y; Moriyama M; Moriyama H; Habu S; Takahashi K
Bosn J Basic Med Sci; 2019 Nov; 19(4):355-367. PubMed ID: 31202256
[TBL] [Abstract][Full Text] [Related]
47. CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines.
Maeda M; Murakami Y; Watari K; Kuwano M; Izumi H; Ono M
Lung Cancer; 2015 Mar; 87(3):265-71. PubMed ID: 25638724
[TBL] [Abstract][Full Text] [Related]
48. Paclitaxel Impedes EGFR-mutated PC9 Cell Growth
Mohiuddin M; Kasahara K
Cancer Genomics Proteomics; 2021; 18(5):645-659. PubMed ID: 34479917
[TBL] [Abstract][Full Text] [Related]
49. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
[TBL] [Abstract][Full Text] [Related]
50. Chronic nicotine exposure affects programmed death-ligand 1 expression and sensitivity to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.
Yeo CD; Kim IK; Ban WH; Kang HS; Kim JW; Kim SJ; Park JY; Lee SH
Transl Cancer Res; 2019 Jul; 8(Suppl 4):S378-S388. PubMed ID: 35117115
[TBL] [Abstract][Full Text] [Related]
51. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
52. Pitavastatin sensitizes the EGFR-TKI associated resistance in lung cancer by inhibiting YAP/AKT/BAD-BCL-2 pathway.
Liu J; Fu J; Fu P; Liu M; Liu Z; Song B
Cancer Cell Int; 2024 Jun; 24(1):224. PubMed ID: 38943199
[TBL] [Abstract][Full Text] [Related]
53. Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line.
Qi HW; Shen Z; Fan LH
Exp Ther Med; 2011 Nov; 2(6):1091-1095. PubMed ID: 22977626
[TBL] [Abstract][Full Text] [Related]
54. Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
Ju L; Zhou C; Li W; Yan L
J Cell Biochem; 2010 Dec; 111(6):1565-74. PubMed ID: 21053345
[TBL] [Abstract][Full Text] [Related]
55. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
[TBL] [Abstract][Full Text] [Related]
56. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
[TBL] [Abstract][Full Text] [Related]
57. The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
Lee Y; Choi YR; Kim KY; Shin DH
Oncotarget; 2016 Jul; 7(28):43315-43323. PubMed ID: 27270313
[TBL] [Abstract][Full Text] [Related]
58. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
[TBL] [Abstract][Full Text] [Related]
59. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
60. Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway.
Zhou J; Qu G; Zhang G; Wu Z; Liu J; Yang D; Li J; Chang M; Zeng H; Hu J; Fang T; Song Y; Bai C
J Exp Clin Cancer Res; 2019 Feb; 38(1):96. PubMed ID: 30791926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]